Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Finnish Biosimilar Substitution Proposals Get Pushback From Industry

Local Association Urges Government To Take A More Gradual Approach

Executive Summary

Finnish government proposals to introduce pharmacy-level substitution for biosimilars have been criticized by the country’s generics and biosimilars industry association.

You may also be interested in...



EMA-HMA Biosimilar Interchangeability Statement Offers ‘Unity And Clarity’ For Europe

The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.

Stakeholders Surprised As French Biosimilar Substitution Changes Tack

The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.

Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount

Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel